May 7, 2020 / 5:27 AM / 23 days ago

BRIEF-Roche’s Genentech Gives Update On Cancer Research

May 7 (Reuters) - Roche Holding AG:

* NEW DATA AT ASCO20 VIRTUAL SCIENTIFIC PROGRAM REFLECTS GENENTECH'S COMMITMENT TO ACCELERATING PROGRESS IN CANCER CARE

* FIRST CLINICAL DATA FROM TIRAGOLUMAB, GENENTECH'S NOVEL ANTI-TIGIT CANCER IMMUNOTHERAPY, IN COMBINATION WITH TECENTRIQ IN PEOPLE WITH PD-L1-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER

* UPDATED OVERALL SURVIVAL DATA FOR ALECENSA IN PEOPLE LIVING WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NSCLC Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below